93 169

Cited 0 times in

Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients

Authors
 Sung Chul Won  ;  Dong Kyun Han  ;  Jong Jin Seo  ;  Nak Gyun Chung  ;  Sang Kyu Park  ;  Kyung Bae Park  ;  Hoon Kook  ;  Chuhl Joo Lyu 
Citation
 Korean Journal of Hepatology (대한간학회지), Vol.45(1) : 58-61, 2010 
Journal Title
 Korean Journal of Hepatology (대한간학회지) 
ISSN
 1738-222X 
Issue Date
2010
Keywords
Deferiprone ; Iron overload ; Transfusion ; Neutropenia
Abstract
BACKGROUND: Iron overload is a predictable and life-threatening complication in patients dependent on the regular transfusion of RBCs. The aims of this study were to investigate the efficacy and safety of deferiprone in a variety of pediatric hematologic and/or oncologic patients with a high iron overload. METHODS: SEVENTEEN PATIENTS (AGE: 1.1-20.4 years; median: 10.6 years) from 7 hospitals who were treated with deferiprone from 2006 to 2009 were enrolled in this study. Medical records of enrolled patients were reviewed retrospectively. RESULTS: Serum ferritin levels were 4,677.8±1,130.9 µg/L at baseline compared to 3,363.9±1,149.7 µg/L at the end of deferiprone treatment (P=0.033). Only 1 patient developed neutropenia as a complication. CONCLUSION: Deferiprone treatment is relatively safe for pediatric patients suffering from various hematologic and oncologic diseases that require RBC transfusions as part of treatment. However, the potential development of critical complications such as agranulocytosis and/or neutropenia remains a concern.
Files in This Item:
T201005336.pdf Download
DOI
10.5045/kjh.2010.45.1.58
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
Yonsei Authors
Won, Sung Chul(원성철)
Lyu, Chuhl Joo(유철주) ORCID logo https://orcid.org/0000-0001-7124-7818
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/103059
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse